COMMUNIQUÉS West-GlobeNewswire

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
23/09/2026
- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34 [...]
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
23/09/2026
The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disorders Vancouver, Canada, Sept. 23, [...]
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
23/09/2026
Appointments support ProQR’s strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipeline AX-0811, the first ProQR program identified through its AI-enabled [...]
PhAST Corp. Receives FDA Clearance for Rapid Antimicrobial Susceptibility Testing Directly From Positive Blood Cultures
23/09/2026
The PhAST BC GN Panel delivers phenotypic susceptibility results in approximately 100 minutes for Enterobacterales and Acinetobacter spp. and 140 minutes for Pseudomonas aeruginosa, directly from positive blood cultures [...]
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
23/09/2026
Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companies BRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: [...]
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
23/09/2026
MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Adaptyx Biosciences Granted FDA Breakthrough Device Designation For Its Continuous Cortisol Monitoring Technology and Is Accepted into FDA’s Total Product Life Cycle Advisory Program
23/09/2026
Designation highlights Adaptyx Biosciences innovation in continuous molecular monitoring and accelerates the pathway for FDA authorization of novel continuous cortisol monitoring device. Menlo Park, CA, Sept. 23, 2026 ( [...]
Altimmune to Participate in Stifel Cardiometabolic Forum
23/09/2026
GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that [...]
SOTIO Advances SOT106 with Dual FDA Designations, Further Positioning the Program as a Potential Best-in-Class ADC for Sarcoma
23/09/2026
Fast Track Designation granted for treatment of osteosarcoma Orphan Drug Designation granted for treatment of soft tissue sarcoma Multiple FDA designations underscores the promise of SOT106 and strengthens the program’s [...]
BioAro Launches AI-Assisted LONgevity+™ Bioactives in the U.S. and U.K.
23/09/2026
Following its Dubai debut, BioAro brings its precision longevity portfolio to two major global health and wellness markets NEW YORK and LONDON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- The longevity industry has no shortage [...]
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
23/09/2026
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of [...]
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
23/09/2026
Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity HOUSTON, Sept. 23, 2026 (GLOBE [...]
Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for November
23/09/2026
This phase 2b/3, double-blind trial of oral Xanamem in 247 participants with mild to moderate Alzheimer’s disease and elevated pTau181 evaluates the potential benefit of targeting excess cortisol in the brain over a 36- [...]
Parexel Transforms Functional Service Provider (FSP) Model to Improve R&D Productivity and Enhance Post-Approval Product Lifecycle Services for Biopharmaceutical Companies
23/09/2026
Integrated FSP model pairs specialist global talent with ParexelAI-enabled technology and operational expertise, enabling sponsors to better flex capacity as pipelines shift RALEIGH, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE [...]
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
23/09/2026
The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression [...]
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
23/09/2026
Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis [...]
Cannabix’s BreathLogix Alcohol Screening Solution Enters U.S. Manufacturing Workplace Market with Deployment at Alabama Facility
23/09/2026
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
23/09/2026
One cGMP batch, manufactured in-house under Optimi's Health Canada Drug Establishment Licence, supplies both the Canadian trial and Australian clinics VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Pycnogenol® Offers Clinically Backed Cognitive Support Across Generations
23/09/2026
Research on French maritime pine bark extract spans children, students, working professionals and older adults looking to stay mentally sharp GENEVA, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brain health is no longer a [...]

Pages